Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

HER2 Genetic Heterogeneity in Gastric Cancer Evaluation According to the College of American Pathologists Breast Cancer Criteria

HER2 Genetic Heterogeneity in Gastric Cancer Evaluation According to the College of American... RESEARCH ARTICLE HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria Ann D. Treacy, MB, MRCPI, FRCPath, FFPath, Jason R. Karamchandani, MD, Catherine J. Streutker, MSc, MD, FRCP(C), and Andrea Grin, MD, FRCP(C) astric cancer is the fourth most common cancer Abstract: Gastric and gastroesophageal junction (GEJ) ad- Gworldwide and is the second most common cause of enocarcinomas have been shown to display significant HER2 cancer-related death. Although advances have been genetic heterogeneity (GH). This is typically seen as a cluster of made in the diagnosis and treatment of gastric and gas- HER2-positive cells but can also take the form of intermingled troesophageal junction (GEJ) adenocarcinoma, the cells, referred to a “mosaic” pattern. GH is not well defined in prognosis of advanced-stage adenocarcinomas remains gastric/GEJ tumors and the “mosaic” pattern has never been poor. In the era of personalized medicine, the role of studied. We sought to evaluate the frequency and distribution of HER2 in gastric/GEJ cancer has been widely welcomed 2,3 the “mosaic” pattern of GH in gastric/GEJ tumors using the as a promising development in cancer treatment. College of American Pathologists-endorsed breast criteria of 5% Approximately 7% to 34% http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

HER2 Genetic Heterogeneity in Gastric Cancer Evaluation According to the College of American Pathologists Breast Cancer Criteria

Applied Immunohistochemistry & Molecular Morphology , Volume Publish Ahead of Print – Jan 1, 2015

Loading next page...
 
/lp/wolters-kluwer-health/her2-genetic-heterogeneity-in-gastric-cancer-evaluation-according-to-P1rt80OCrW

References (16)

Copyright
Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
ISSN
1541-2016
DOI
10.1097/PAI.0000000000000136
pmid
25611242
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria Ann D. Treacy, MB, MRCPI, FRCPath, FFPath, Jason R. Karamchandani, MD, Catherine J. Streutker, MSc, MD, FRCP(C), and Andrea Grin, MD, FRCP(C) astric cancer is the fourth most common cancer Abstract: Gastric and gastroesophageal junction (GEJ) ad- Gworldwide and is the second most common cause of enocarcinomas have been shown to display significant HER2 cancer-related death. Although advances have been genetic heterogeneity (GH). This is typically seen as a cluster of made in the diagnosis and treatment of gastric and gas- HER2-positive cells but can also take the form of intermingled troesophageal junction (GEJ) adenocarcinoma, the cells, referred to a “mosaic” pattern. GH is not well defined in prognosis of advanced-stage adenocarcinomas remains gastric/GEJ tumors and the “mosaic” pattern has never been poor. In the era of personalized medicine, the role of studied. We sought to evaluate the frequency and distribution of HER2 in gastric/GEJ cancer has been widely welcomed 2,3 the “mosaic” pattern of GH in gastric/GEJ tumors using the as a promising development in cancer treatment. College of American Pathologists-endorsed breast criteria of 5% Approximately 7% to 34%

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Jan 1, 2015

There are no references for this article.